Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Neuvonen

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 3, 2015
Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate SimvastatinMatti K Itkonen, Aleksi Tornio, Mikko Neuvonen, et al.
Drugs & Aging|December 23, 2010
Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groupsAntti Liukas, Kristiina Kuusniemi, Riku Aantaa, et al.
Clinical and Translational Science|September 29, 2021
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokineticsPäivi Hirvensalo, Aleksi Tornio, Tuija Tapaninen, et al.
Clinical Pharmacology and Therapeutics|June 24, 2017
Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?Kristiina Cajanus, Mikko Neuvonen, Outi Koskela, et al.
British Journal of Clinical Pharmacology|August 22, 2009
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatinJenni E Keskitalo, Kaisa J Kurkinen, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|October 10, 2003
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinideMikko Niemi, Julian B Leathart, Mikko Neuvonen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 28, 2014
Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye dropsJukka Mäenpää, Marjo Volotinen-Maja, Hannu Kautiainen, et al.
British Journal of Clinical Pharmacology|January 6, 2015
Effect of grapefruit juice on the bioactivation of prasugrelMikko T Holmberg, Aleksi Tornio, Hanna Hyvärinen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2009
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probeJanne T Backman, Johanna Honkalammi, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 29, 2024
Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitorsHelinä Kahma, Marie-Noëlle Paludetto, Mikko Neuvonen, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 3, 2015
Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate SimvastatinMatti K Itkonen, Aleksi Tornio, Mikko Neuvonen, et al.
Drugs & Aging|December 23, 2010
Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groupsAntti Liukas, Kristiina Kuusniemi, Riku Aantaa, et al.
Clinical and Translational Science|September 29, 2021
Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokineticsPäivi Hirvensalo, Aleksi Tornio, Tuija Tapaninen, et al.
Clinical Pharmacology and Therapeutics|June 24, 2017
Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?Kristiina Cajanus, Mikko Neuvonen, Outi Koskela, et al.
British Journal of Clinical Pharmacology|August 22, 2009
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatinJenni E Keskitalo, Kaisa J Kurkinen, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|October 10, 2003
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinideMikko Niemi, Julian B Leathart, Mikko Neuvonen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 28, 2014
Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye dropsJukka Mäenpää, Marjo Volotinen-Maja, Hannu Kautiainen, et al.
British Journal of Clinical Pharmacology|January 6, 2015
Effect of grapefruit juice on the bioactivation of prasugrelMikko T Holmberg, Aleksi Tornio, Hanna Hyvärinen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2009
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probeJanne T Backman, Johanna Honkalammi, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 29, 2024
Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitorsHelinä Kahma, Marie-Noëlle Paludetto, Mikko Neuvonen, et al.
Pageof 11